News and Announcements
Proteomics PromarkerD Update
- Published March 07, 2016 12:50PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
7th March 2016, ASX Announcement
Highlights:
- Follow up, validation study on 500 patient cohort underway – results to be announced in due course.
- Company is instigating its own development program to produce a standard clinical pathology In vitro Diagnostic (IVD) test kit for PromarkerD.
- PILL to present to key bio-analytical sector decision markers at invitation only events in the USA this week.
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to provide the following market update on PromarkerD, the world’s first proteomics-derived predictive (prognostic) test for the diagnosis of Diabetic Kidney Disease.
Partnering and Licensing Progress
PILL remains in ongoing discussions with a number of diagnostic and pharmaceutical companies in global markets, including USA, Europe, Japan and Latin America, for the commercialisation of PromarkerD. As part of this process, PILL has been in discussion with a major global health care company (potential partner) for a period of 11 months in relation to the partnering and licencing of PromarkerD. These discussions continue to progress in a positive manner.
To view the full announcement, please click here.